It followed that cancer samples with most TP53 mutations must overexpress CD24. By showing a 2.6-fold enrichment of TP53 mutations among CD24 amplified samples, the data presented here provided further clinical support for the interaction between CD24 and TP53 (Wang et al., 2015; Li et al., 2018). This evidence concerns the gene CD24 and cancer.